AACR22: Rubius touts new data for lead program, but shares routed as investors flee

 Looking to build on its first cut of human data from last year, Rubius Therapeutics is touting new Phase I data from its lead cancer program in both solid tumors and acute myeloid leukemia. But the results proved sorely disappointing to investors after appearing to be less effective than the previous readout.

https://endpts.com/aacr22-rubius-touts-new-data-for-lead-program-but-will-it-prove-effective-enough-for-investors/